LFCR

Company Overview — What Does LIFECORE BIOMEDICAL, INC. \DE\ Do?

Landec Corporation, together with its subsidiaries, engages in the design, development, manufacture, and sale of differentiated health and wellness products for food and biomaterials markets. It operates through Curation Foods and Lifecore segments. The Curation Foods segment engages in processing, marketing, and selling of plant-based salads, and fresh-cut and whole processed vegetables primarily under the Eat Smart brand, O branded olive oils and wine vinegars, and Yucatan and Cabo Fresh guacamole and avocado food products, as well as various private labels to retail grocery chains, club stores, and food service operators; and sells BreatheWay packaging products. The Lifecore segment manufactures pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products to treat various medical conditions and procedures. It also provides product development services, including technology transfer, material component changes, analytical method and formulation development, pilot and stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. It operates in the United States, Canada, Belgium, Switzerland, Czech Republic, Ireland, and internationally. The company was incorporated in 1986 and is headquartered in Santa Maria, California. LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO James G. Hall and employs approximately 690 people, headquartered in SANTA CLARA, Minnesota. With a market capitalization of $144M, LFCR is one of the notable companies in the Healthcare sector.

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) Stock Rating — Reduce (April 2026)

As of April 2026, LIFECORE BIOMEDICAL, INC. \DE\ receives a Reduce rating with a composite score of 30.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.LFCR ranks #3,858 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, LIFECORE BIOMEDICAL, INC. \DE\ ranks #654 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LFCR Stock Price and 52-Week Range

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) currently trades at $4.78. The stock gained $0.06 (1.3%) in the most recent trading session. The 52-week high for LFCR is $8.98, which means the stock is currently trading -46.8% from its annual peak. The 52-week low is $4.09, putting the stock 16.9% above its annual trough. Recent trading volume was 493K shares, suggesting relatively thin trading activity.

Is LFCR Overvalued or Undervalued? — Valuation Analysis

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 7.48x, versus the sector average of 2.75x. The price-to-sales ratio is 1.25x, compared to 1.66x for the average Healthcare stock.

At current multiples, LIFECORE BIOMEDICAL, INC. \DE\ trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

LIFECORE BIOMEDICAL, INC. \DE\ Profitability — ROE, Margins, and Quality Score

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -45.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -20.2% versus the sector average of -33.1%.

On a margin basis, LIFECORE BIOMEDICAL, INC. \DE\ reports gross margins of 27.2%, compared to 71.5% for the sector. The operating margin is -22.1% (sector: -66.1%). Net profit margin stands at -40.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -12.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LFCR Debt, Balance Sheet, and Financial Health

LIFECORE BIOMEDICAL, INC. \DE\ has a debt-to-equity ratio of 367.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.80x, indicating strong short-term liquidity. Total debt on the balance sheet is $136M.

LFCR has a beta of 1.60, meaning it is more volatile than the broader market — a $10,000 investment in LFCR would be expected to move 59.6% more than the S&P 500 on any given day. The stability factor score for LIFECORE BIOMEDICAL, INC. \DE\ is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

LIFECORE BIOMEDICAL, INC. \DE\ Revenue and Earnings History — Quarterly Trend

In TTM 2026, LIFECORE BIOMEDICAL, INC. \DE\ reported revenue of $124M and earnings per share (EPS) of $-0.29. Net income for the quarter was $-48M. Gross margin was 27.2%. Operating income came in at $-26M.

In Q1 2026, LIFECORE BIOMEDICAL, INC. \DE\ reported revenue of $31M and earnings per share (EPS) of $-0.29. Net income for the quarter was $-10M. Gross margin was 25.0%. Revenue grew 25.9% year-over-year compared to Q1 2025. Operating income came in at $-3M.

In FY 2025, LIFECORE BIOMEDICAL, INC. \DE\ reported revenue of $129M and earnings per share (EPS) of $-1.27. Net income for the quarter was $-39M. Gross margin was 31.3%. Revenue grew 0.5% year-over-year compared to FY 2024. Operating income came in at $-17M.

In Q3 2025, LIFECORE BIOMEDICAL, INC. \DE\ reported revenue of $35M and earnings per share (EPS) of $-0.47. Net income for the quarter was $-15M. Gross margin was 28.0%. Revenue grew -1.5% year-over-year compared to Q3 2024. Operating income came in at $-9M.

Over the past 8 quarters, LIFECORE BIOMEDICAL, INC. \DE\ has demonstrated a growth trajectory, with revenue expanding from $36M to $124M. Investors analyzing LFCR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LFCR Dividend Yield and Income Analysis

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LFCR Momentum and Technical Analysis Profile

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) has a momentum factor score of 26/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 37/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 46/100 reflects moderate short selling activity.

LFCR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) ranks #654 out of 838 stocks based on the Blank Capital composite score. This places LFCR in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LFCR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LFCR vs S&P 500 (SPY) comparison to assess how LIFECORE BIOMEDICAL, INC. \DE\ stacks up against the broader market across all factor dimensions.

LFCR Next Earnings Date

No upcoming earnings date has been announced for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LFCR? — Investment Thesis Summary

The quantitative profile for LIFECORE BIOMEDICAL, INC. \DE\ suggests caution. The quality score of 27/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. Momentum is weak at 26/100, a headwind for near-term performance. High volatility (stability score 27/100) increases portfolio risk.

In summary, LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) earns a Reduce rating with a composite score of 30.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LFCR stock.

Related Resources for LFCR Investors

Explore more research and tools: LFCR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LFCR head-to-head with peers: LFCR vs AZN, LFCR vs SLGL, LFCR vs VMD.